Skip to main content

Table 2 Lung function and QoL-questionnaires

From: Effects of long-term tobramycin inhalation solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis

Lung function and QoL-questionnaires

TIS

  

Placebo

  
 

Start

End

p-value

Start

End

p-value

Pulmonary function

      

 FEV1% predicted, mean (SD)

65.9 (24.9)

72.7 (23.0)

0.58

70.5 (24.0)

73.2 (23.5)

0.21

 FVC% predicted, mean (SD)

84.4 (20.1)

85.0 (24.3)

0.32

90.2 (18.6)

90.3 (19.5)

0.52

QoL-Bronchiectasis questionnaire, mean (SD)

      

 QoL-B Physical

49.8 (30.0)

47.6 (27.4)

0.75

42.5 (34.8)

42.7 (38.4)

0.47

 QoL-B Role

64.4 (24.7)

65.1 (20.7)

0.81

59.2 (23.9)

57.9 (23.9)

0.77

 QoL-B Vitality

53.1 (17.4)

51.5 (18.7)

0.85

48.7 (17.6)

45.5 (24.5)

0.25

 QoL-B Emotional

87.9 (10.5)

83.3 (11.2)

0.05

82.4 (16.5)

84.1 (12.8)

0.57

 QoL-B Social

65.0 (20.9)

64.8 (16.8)

0.81

60.1 (23.4)

67.2 (18.6)

0.10

 QoL-B Treatment Burden

66.4 (17.9)

63.9 (24.2)

0.66

64.0 (19.4)

62.8 (21.7)

0.75

 QoL-B Health perceptions

42.4 (16.8)

48.1 (19.7)

0.08

43.2 (18.9)

46.1 (17.5)

0.24

 QoL-B respiratory symptoms

56.1 (17.8)

61.0 (17.4)

0.05

57.8 (16.7)

59.8 (17.9)

0.14

LRTI-VAS total score, mean (SD)

21.0 (7.3)

18.0 (7.5)

0.02

21.0 (8.5)

20.0 (7.1)

0.18

Leicester Cough total score, mean (SD)

13.4 (2.9)

14.5 (3.2)

0.02

13.8 (4.2)

15.1 (2.6)

0.09

  1. Lung function and QoL questionnaires of the mITT population. Data are presented as mean (SD). A decrease in LRTI-VAS score corresponds to clinical improvement. Tobramycin Inhalation Solution (TIS); Forced expiratory volume in one second (FEV1); Forced vital capacity (FVC); Quality of life (QoL); Quality of life bronchiectasis questionnaire (QoL-B); Lower respiratory tract infections—Visual Analogue Scale (LRTI-VAS); Leicester cough questionnaire (Leicester cough)